Alpha 2.0
Login Register
» Authors » Katsuhiro Hayashi

Katsuhiro Hayashi

Explore the profile of Katsuhiro Hayashi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 316
Citations 3165
Followers 0
Related Specialties
Oncology
Orthopedics
Biochemistry
Top 10 Co-Authors
Hiroyuki Tsuchiya
Norio Yamamoto
Shinji Miwa
Akihiko Takeuchi
Kentaro Igarashi
Hiroaki Kimura
Takashi Higuchi
Robert M Hoffman
Sei Morinaga
Yuta Taniguchi
Published In
Anticancer Res
J Orthop Sci
J Cell Biochem
BMC Musculoskelet Disord
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Highly Synergistic Eradication of 143B Osteosarcoma Cells by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, Respectively
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Anticancer Res . 2025 Mar; 45(3):935-941. PMID: 40037880
Background/aim: Drug-resistant osteosarcoma is a highly aggressive malignancy with limited therapeutic options. Recombinant methioninase (rMETase) targets the methionine addiction of cancer and acts synergistically with many cancer-chemotherapy agents. The present...
2.
Comparative surgical invasiveness of internal fixation for pathological fractures in metastatic bone disease versus traumatic fractures: a quantitative analysis of operative time and blood loss
Hayashi K, Takenaka S, Ohshika S, Kawashima H, Endo M, Kobayashi E, et al.
Jpn J Clin Oncol . 2025 Mar; PMID: 40036267
Objective: The primary aim of this study was to compare the surgical invasiveness of internal fixation for pathological fractures caused by metastatic bone tumors with that for traumatic fractures. The...
3.
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo . 2025 Feb; 39(2):683-690. PMID: 40010975
Background/aim: Trabectedin is a DNA-binding agent that has shown moderate efficacy for soft-tissue sarcomas. We have previously shown that methionine restriction enhances trabectedin efficacy on both parental and trabectedin-resistant HT1080...
4.
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice
Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo . 2025 Feb; 39(2):640-647. PMID: 40010967
Background/aim: A1-R (A1-R) expresses green fluorescent protein (GFP) and has the ability to selectively target and inhibit all major cancer types in murine models without persistently infecting healthy tissue. A1-R...
5.
Predictive variables for intraoperative blood loss and surgical time in resection of malignant soft tissue tumors without reconstruction
Nakamura T, Kobayashi E, Takenaka S, Endo M, Hayashi K, Nakata E, et al.
Jpn J Clin Oncol . 2025 Feb; PMID: 39957416
Background: Procedural techniques such as dissection and separation of blood vessels or nerves from the tumor for preserving limbs and functions involves high surgical difficulty. We hypothesized the relation of...
6.
Clinicopathological background of local recurrence in high grade sarcoma of the extremity with preoperative chemotherapy: a supplementary analysis of JCOG0304
Tsukushi S, Tanaka K, Kunisada T, Machida R, Takenaka S, Kawai A, et al.
Jpn J Clin Oncol . 2025 Feb; PMID: 39918167
Background: The mainstay of treatment for soft-tissue sarcomas is complete resection with negative surgical margins. However, treatment strategies for local control including the frequency of adjuvant radiotherapy (RT) and surgical...
7.
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
Morinaga S, Han Q, Mizuta K, Kang B, Hozumi C, Bouvet M, et al.
Anticancer Res . 2025 Jan; 45(2):451-455. PMID: 39890170
Background/aim: Ivermectin is a widely-used anti-parasitic agent and has shown early promise as an anticancer agent. Recombinant methioninase (rMETase) is a methionine-depleting enzyme targeting the methionine addiction of cancer and...
8.
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing
Morinaga S, Han Q, Mizuta K, Kang B, Yamamoto N, Hayashi K, et al.
Cancer Diagn Progn . 2025 Jan; 5(1):27-31. PMID: 39758238
Background/aim: Metastatic prostate cancer is a recalcitrant disease. Our laboratory has previously treated prostate-cancer patients with methionine restriction effected by a low methionine diet and oral recombinant methioninase (o-rMETase), both...
9.
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Cancer Diagn Progn . 2025 Jan; 5(1):8-14. PMID: 39758233
Background/aim: For second-line chemotherapy of soft-tissue sarcoma, gemcitabine is administered in combination with docetaxel. However, more effective treatments are required for advanced soft-tissue sarcoma, where the efficacy is limited. The...
10.
Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line Chemotherapy
Morinaga S, Han Q, Mizuta K, Kang B, Yamamoto N, Hayashi K, et al.
Cancer Diagn Progn . 2025 Jan; 5(1):21-26. PMID: 39758229
Background/aim: Chronic lymphocytic leukemia (CLL) is currently incurable. CLL is characterized by disordered DNA methylation. The aim of the present study was to target methylation with methionine restriction in a...